<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126056</url>
  </required_header>
  <id_info>
    <org_study_id>NGH2</org_study_id>
    <nct_id>NCT05126056</nct_id>
  </id_info>
  <brief_title>Lipid Lowering Effect of Plant Stanol Ester in a Drinkable Non-dairy Product</brief_title>
  <official_title>Lipid Lowering Effect of Plant Stanol Ester in a Drinkable Non-dairy Product</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raisio Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Raisio Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to determine the effect of investigational products on serum LDL cholesterol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in low-density lipoprotein (LDL) cholesterol concentration (%)</measure>
    <time_frame>0 vs 3 weeks</time_frame>
    <description>Mean relative change in serum LDL cholesterol concentration during the intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol concentration</measure>
    <time_frame>0 vs 3 weeks</time_frame>
    <description>Mean absolute change in serum LDL cholesterol concentration during the intervention between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total cholesterol concentration</measure>
    <time_frame>0 vs 3 weeks</time_frame>
    <description>Changes in serum total cholesterol concentration during the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High density lipoprotein (HDL) cholesterol concentration</measure>
    <time_frame>0 vs 3 weeks</time_frame>
    <description>Changes in serum HDL cholesterol concentration during the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-HDL cholesterol concentration</measure>
    <time_frame>0 vs 3 weeks</time_frame>
    <description>Changes in serum non-HDL cholesterol concentration during the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total triglyceride concentration</measure>
    <time_frame>0 vs 3 weeks</time_frame>
    <description>Changes in serum triglycerides concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nuclear magnetic resonance (NMR) blood biomarkers</measure>
    <time_frame>0 vs 3 weeks</time_frame>
    <description>Changes in specific NMR blood biomarkers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Products that contain plant stanol ester. Product with active ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo product. Product without active ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plant stanol ester</intervention_name>
    <description>Product with active ingredient vs product without active ingredient</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Mildly or moderately elevated plasma cholesterol levels (plasma total cholesterol&#xD;
             5.5-8.0 mmol/l)&#xD;
&#xD;
          -  Plasma triglyceride levels ≤ 4.0 mmol/l&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intolerance to oats or other ingredients of the test products&#xD;
&#xD;
          -  Severe obesity (BMI ≥ 32 kg/m2)&#xD;
&#xD;
          -  Consumption of lipid/cholesterol lowering medication (e.g. ezetimibe, PCSK9&#xD;
             inhibitors, resins, fibrates) 1 month prior to the screening visit and throughout the&#xD;
             study. Statin treatment is allowed at stable dose.&#xD;
&#xD;
          -  Consumption of plant stanol or plant sterol containing food products or supplements or&#xD;
             other foods or supplements such as beta-glucan enriched foods, red rice, berberine or&#xD;
             any combination of these used for cholesterol lowering purpose 1 month prior the study&#xD;
             entry (baseline blood sample)&#xD;
&#xD;
          -  History of malignant diseases like cancer within five years prior to recruitment&#xD;
&#xD;
          -  History of unstable coronary artery disease (myocardial infarction, coronary artery&#xD;
             bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA) within the&#xD;
             previous 6 months&#xD;
&#xD;
          -  Diagnosed type 1 or type 2 diabetes requiring medical treatment&#xD;
&#xD;
          -  Celiac disease&#xD;
&#xD;
          -  Medically prescribed diet/treatment for slimming or a special diet like very low&#xD;
             calorie diet or use of prescribed an obesity drug (e.g. Orlistat, Victoza)&#xD;
&#xD;
          -  Alcohol abuse (&gt; 4 portion/per day) or recreational drug abuse&#xD;
&#xD;
          -  Pregnancy or planned pregnancy or lactating&#xD;
&#xD;
          -  Clinically significant abnormalities in screening labs&#xD;
&#xD;
          -  Participation in another clinical trial in the preceding 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Gylling</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Hospital, Helsinki, Finland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helena Gylling, Prof, MD</last_name>
    <phone>+358503302402</phone>
    <email>helena.gylling@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Würtz, prof, MD</last_name>
    <phone>+358207301812</phone>
    <email>peter.wurtz@nightingalehealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nightingale Health plc</name>
      <address>
        <city>Helsinki</city>
        <zip>00330</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Würtz, PhD</last_name>
      <phone>+358 20 730 1812</phone>
      <email>peter.wurtz@nightingalehealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

